{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:56:56Z","timestamp":1792695416497,"version":"4.5.0"},"reference-count":48,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Antimuscarinics and the \u03b23\u2010adrenoreceptor agonist, mirabegron, are commonly used for treating patients with overactive bladder (OAB) and \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoreceptor antagonists (\u03b1<jats:sub>1<\/jats:sub>\u2010blockers) are the main pharmacological agents used for treating lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). As these conditions commonly occur together, the aim of this systematic review was to identify publications that compared the use of an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus mirabegron with an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus antimuscarinic in men with LUTS secondary to BPH and OAB. A meta\u2010analysis was subsequently conducted to explore the safety and efficacy of these combinations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Included records had to be from a parallel\u2010group, randomized clinical trial that was \u22658 weeks in duration. Participants were male with LUTS secondary to BPH and OAB. The indirect analyses that were identified compared an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus OAB agent with an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus placebo. The PubMed\/Medical Literature Analysis and Retrieval System Online, the Excerpta Medica Database, the Cochrane Central Register of Controlled Trials, and the <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> registry were searched for relevant records up until March 5, 2020. Safety outcomes included incidences of overall treatment\u2010emergent adverse events (TEAEs) and urinary retention, postvoid residual volume, and maximum urinary flow (<jats:italic>Q<\/jats:italic><jats:sub>max<\/jats:sub>). Primary efficacy outcomes were micturitions\/day, incontinence episodes\/day, and urgency episodes\/day, and secondary outcomes were Overactive Bladder Symptom Score\u00a0and International Prostate Symptom Score. A Bayesian network meta\u2010analysis approach was used for the meta\u2010analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Out of a total of 1039 records identified, 24 were eligible for inclusion in the meta\u2010analysis. There were no statistically significant differences between the \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus mirabegron and \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus antimuscarinic groups in terms of the comparisons identified for all the safety and efficacy analyses conducted. Numerically superior results were frequently observed for the \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus mirabegron group compared with the \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus antimuscarinic group for the safety parameters, including TEAEs, urinary retention, and <jats:italic>Q<\/jats:italic><jats:sub>max<\/jats:sub>. For some of the efficacy parameters, most notably micturitions\/day, numerically superior results were noted for the \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus antimuscarinic group. Inconsistency in reporting and study variability were noted in the included records, which hindered data interpretation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This systematic review and meta\u2010analysis showed that an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus mirabegron and an \u03b1<jats:sub>1<\/jats:sub>\u2010blocker plus antimuscarinic have similar safety and efficacy profiles in male patients with LUTS secondary to BPH and OAB. Patients may, therefore, benefit from the use of either combination within the clinical setting.<\/jats:p><\/jats:sec>","DOI":"10.1002\/nau.25399","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T07:09:32Z","timestamp":1706684972000},"page":"604-619","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety and efficacy of an \u03b1<sub>1<\/sub>\u2010blocker plus mirabegron compared with an \u03b1<sub>1<\/sub>\u2010blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta\u2010analysis"],"prefix":"10.1002","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8666-8236","authenticated-orcid":false,"given":"Sender","family":"Herschorn","sequence":"first","affiliation":[{"name":"Department of Surgery\/Urology, Sunnybrook Health Sciences Centre University of Toronto Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-3524","authenticated-orcid":false,"given":"Tufan","family":"Tarcan","sequence":"additional","affiliation":[{"name":"Department of Urology, School of Medicine Marmara University Istanbul Turkey"},{"name":"Department of Urology, School of Medicine Ko\u00e7 University Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan\u2010Hong","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Urology, Buddhist Tzu Chi General Hospital Tzu Chi University Hualien Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3373-3668","authenticated-orcid":false,"given":"Eric","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Urology, Princess Alexandra Hospital The University of Queensland Brisbane Queensland Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Abdul Hadi","sequence":"additional","affiliation":[{"name":"Astellas Pharma Singapore Pte. Ltd. Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Steup","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Budiwan","family":"Sumarsono","sequence":"additional","affiliation":[{"name":"Astellas Pharma Singapore Pte. Ltd. Singapore Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.09.146"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12193"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.21072"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.10013.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2016.04.001"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jocn.12636"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12335"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/820816"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.047"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.03.020"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.01.074"},{"key":"e_1_2_9_13_1","first-page":"155","article-title":"Tamsulosin, the first prostate\u2010selective alpha 1A\u2010adrenoceptor antagonist. A meta\u2010analysis of two randomized, placebo\u2010controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group","volume":"29","author":"Chapple CR","year":"1996","journal-title":"Eur Urol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(96)00208-7"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80449-X"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.02.055"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000738"},{"key":"e_1_2_9_18_1","unstructured":"PRISMA. Transparent reporting of systematic reviews and meta\u2010analyses. \u00a9 Copyright 2023 PRISMA. Accessed December 1 2023.http:\/\/www.prisma-statement.org\/"},{"key":"e_1_2_9_19_1","unstructured":"HigginsJ ThomasJ. Cochrane handbook for systematic reviews of interventions. Version 6.4 2023. Accessed December 1 2023.https:\/\/training.cochrane.org\/handbook\/current"},{"key":"e_1_2_9_20_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2012.02.1569","article-title":"Prospective randomized trial of alpha\u2010blocker combined with imidafenacin in the treatment of nocturia in patients with benign prostatic hyperplasia and concomitant overactive bladder syndrome: results of GOOD\u2010NIGHT study","volume":"187","author":"Inamoto T","year":"2012","journal-title":"J Urol"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000173630.94559.fd"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2011.22"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23013"},{"key":"e_1_2_9_24_1","first-page":"PC08","article-title":"\u2018Tamsulosin and darifenacin\u2019 versus \u2018tamsulosin monotherapy\u2019 for \u2018BPH with accompanying overactive bladder\u2019","volume":"9","author":"Singh I","year":"2015","journal-title":"J Clin Diagn Res"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2013.05.008"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1002"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1757-5672.2010.00081.x"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.08.023"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2012.07.003"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.4111\/kju.2014.55.9.608"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1080\/13685538.2017.1398723"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12124"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13721"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.334.12757"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.19.2319"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.07761.x"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.05.050"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-5538.IBJU.2013.04.09"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.4111\/icu.2020.61.4.419"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.09.091"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2019.10.019"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-020-03425-3"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23863"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1159\/000361079"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000027469"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.11.010"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13498"},{"key":"e_1_2_9_48_1","first-page":"S403","article-title":"Mirabegron versus tolterodine for the treatment of overactive bladder: a meta\u2010analysis of five randomized controlled trials","volume":"34","author":"Naser O","year":"2015","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018802"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.25399","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T05:39:55Z","timestamp":1718948395000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.25399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/nau.25399"],"URL":"https:\/\/doi.org\/10.1002\/nau.25399","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"2023-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}